Marinus Pharmaceuticals Inc (MRNS) Shares Bought by Gabelli Funds LLC

Gabelli Funds LLC grew its stake in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 58.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,000 shares of the biopharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. Gabelli Funds LLC’s holdings in Marinus Pharmaceuticals were worth $113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Rhumbline Advisers raised its position in shares of Marinus Pharmaceuticals by 15.8% during the 1st quarter. Rhumbline Advisers now owns 55,755 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 7,592 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Marinus Pharmaceuticals by 1,465.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,047 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 9,405 shares in the last quarter. Bailard Inc. acquired a new stake in shares of Marinus Pharmaceuticals during the 1st quarter valued at approximately $138,000. Geode Capital Management LLC raised its position in shares of Marinus Pharmaceuticals by 34.7% during the 4th quarter. Geode Capital Management LLC now owns 464,483 shares of the biopharmaceutical company’s stock valued at $1,332,000 after acquiring an additional 119,668 shares in the last quarter. Finally, 683 Capital Management LLC raised its position in shares of Marinus Pharmaceuticals by 22.7% during the 4th quarter. 683 Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock valued at $3,875,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 65.39% of the company’s stock.

Shares of NASDAQ MRNS opened at $4.50 on Friday. Marinus Pharmaceuticals Inc has a 1-year low of $2.36 and a 1-year high of $10.54. The firm has a market capitalization of $244.38 million, a price-to-earnings ratio of -5.00 and a beta of 3.25.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). Equities analysts anticipate that Marinus Pharmaceuticals Inc will post -0.86 EPS for the current fiscal year.

MRNS has been the topic of several research reports. Leerink Swann initiated coverage on Marinus Pharmaceuticals in a research report on Wednesday, February 6th. They set an “outperform” rating and a $10.00 price target on the stock. Svb Leerink reissued an “outperform” rating on shares of Marinus Pharmaceuticals in a research report on Wednesday, February 6th. Zacks Investment Research lowered Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Mizuho lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $13.00 to $5.00 in a research report on Wednesday, February 27th. Finally, Jefferies Financial Group initiated coverage on Marinus Pharmaceuticals in a research report on Tuesday, March 5th. They set a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $14.94.

ILLEGAL ACTIVITY NOTICE: “Marinus Pharmaceuticals Inc (MRNS) Shares Bought by Gabelli Funds LLC” was published by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/2019/05/19/marinus-pharmaceuticals-inc-mrns-shares-bought-by-gabelli-funds-llc.html.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Recommended Story: Different Options Trading Strategies

Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.